

Annual Report 2025

Fondation Campus Biotech Geneva

BRAIN SCIENCE.
TECHNOLOGY.
IMPACT.

Foreword

Dear readers,

The Campus Biotech Geneva Foundation (FCBG) embodies a center of excellence and innovation in the field of neuroscience and neurotechnology. By promoting close collaboration between academic institutions, university hospitals, and industrial partners, it has strengthened its position among leading international research centers.

Over the past year, its cutting-edge technology platforms have accelerated numerous innovative projects, demonstrating its ongoing commitment to advancing science for the benefit of society. The FCBG's development is part of a dynamic and collaborative ecosystem, where each partner makes a decisive contribution to collective success.

We extend our sincere thanks to all our employees who, through their expertise and daily commitment, make the Foundation a key player in biomedical research.

The future looks particularly promising, driven by ambitious projects designed to further strengthen the FCBG's impact and influence.

We invite you to discover this year's highlights and share this exciting adventure with us.

Prof. Audrey Leuba, President
Dr. Nicolas Durand, CEO

Table of Contents

6 MISSION & VISION

7 KEY FIGURES

8 THE FCBG ECOSYSTEM

11 GOVERNANCE

12 RETROSPECTIVE

14 MANAGEMENT TEAM

15 ACADEMIC COUNCIL

16 PLATFORM ADVISORY COMMITTEES (PACs)

18 FCBG PARTNERS

20 MAGNETIC RESONANCE IMAGING PLATFORM (MRI)

22 M/EEG & NEUROMODULATION PLATFORM (MEG)

24 PRECLINIC NEUROSCIENCE PLATFORM (PNP)











26 VIRTUAL REALITY & DIGITAL ENGINEERING PLATFORM (VRD)

28 NEURONA HUMAN CELLULAR NEUROSCIENCE PLATFORM (HCNP)

30 NEURAL MICROSYSTEMS PLATFORM (NMP)

32 CLINICAL & SLEEP RESEARCH PLATFORM (CSR)

34 HEALTH 2030 GENOME CENTER (GC)

36 HUG OUTPATIENT NEUROCLINIC

38 OUR SERVICES

42 RESEARCH & INNOVATION

45 STRATEGIC INNOVATION

46 FINANCIALS

48 VISION

Mission & Vision

The Fondation Campus Biotech Geneva (FCBG)

OUR MISSION

The FCBG's mission is to support and accelerate research and innovation in the field of neuroscience and neurotechnology by providing researchers, clinicians and entrepreneurs with access to cutting-edge infrastructure and technology platforms. Through a collaborative ecosystem, the FCBG catalyses scientific discoveries to maximise their positive impact on society.

By facilitating access to state-of-the-art research equipment and supporting the development of innovative projects, the Foundation plays a key role in promoting translational research and transferring scientific advances to industry.

OUR VISION

Our ambition is to position FCBG as a world-renowned centre of excellence and innovation, where the boundaries between scientific and technological disciplines are blurred in order to respond to the major challenges of our time. We want to create a dynamic and inspiring environment that fosters synergy between researchers, engineers and entrepreneurs in order to accelerate the development of innovative solutions that benefit patients and society.

In a constantly changing world, the FCBG is committed to anticipating scientific and technological trends in the fields of neuroscience and neurotechnology, encouraging interdisciplinarity and promoting responsible and sustainable research. Through a collaborative approach and proactive governance, we aspire to strengthen the impact of our initiatives and make the Foundation a key player in biomedical research and health technologies.



Key figures

10+
platforms
and services

500+
active users on our
platforms

27,600 m^2
infrastructure

70+
research groups

15,500 m^2
laboratories and
experimental spaces

3
NCCRs actively
supported

1,200
people on site

63
FCBG collaborators
(30% PhD & 25% MSc)



ANNUAL BUDGET
CHF 30M

The FCBG ecosystem

One of the world's top 10 leading centers for neuroscience and neurotechnology research

The FCBG on the Campus Biotech site

Campus Biotech is Geneva's leading life sciences ecosystem, promoting interaction and collaboration between institutions, companies and researchers. Its current site is part of Geneva's industrial heritage, occupying the former red brick buildings of the engineering company Sécheron SA, a flagship of Swiss industry. In 2003, these facilities were acquired by the biotechnology company Serono to establish its global headquarters. Following the acquisition of Serono by Merck KGaA and their decision to relocate their operations outside Switzerland, Campus Biotech was created to reinvest in this space and its facilities for the benefit of scientific research and development in the Lake Geneva region.



The blue areas indicate FCBG activities, while the green areas correspond to those of other partners present on the Campus Biotech site.

Campus Biotech is now the main ecosystem dedicated to life sciences in Geneva, actively contributing to the implementation of the cantonal innovation strategy.

The FCBG hosts leading academic and institutional players, including teams recognized nationally for their expertise in neuroscience and neurotechnology, with a reach extending well beyond Switzerland's borders.



OUR FOUNDING MEMBERS

EPFL

The École Polytechnique Fédérale de Lausanne (EPFL) is one of Europe's most prestigious research and teaching institutions, renowned for its excellence in science, engineering, and technology. Located on the shores of Lake Geneva, it attracts students, researchers, and entrepreneurs from around the world, fostering a dynamic ecosystem of innovation and collaboration. With its state-of-the-art infrastructure and close ties to industry, EPFL plays a key role in the development of advanced technological solutions, ranging from artificial intelligence to biotechnology, sustainable energy, and robotics.

UNIVERSITÉ DE GENÈVE

The University of Geneva (UNIGE) is a renowned academic institution, recognized for the excellence of its teaching and research in a wide range of disciplines, from natural and medical sciences to humanities and social sciences. Founded in 1559, it is now a key player on the international academic scene, collaborating closely with numerous organizations, particularly those based in Geneva, such as the UN and WHO. With its strong roots in a cosmopolitan and open-minded city, UNIGE fosters a stimulating intellectual environment conducive to innovation and critical thinking. Its commitment to sustainable development, diversity, and interdisciplinarity makes it a center of academic excellence serving society.

Hôpitaux Universitaires Genève

The Geneva University Hospitals (HUG) are one of Switzerland's leading hospital centres and a centre of excellence in healthcare, teaching and medical research. Associated with the Faculty of Medicine of the University of Geneva, they offer cutting-edge expertise in many fields, ranging from precision medicine to transplantation, neuroscience and oncology. Thanks to their modern infrastructure and commitment to innovation, the HUG actively contributes to the advancement of medical knowledge and the continuous improvement of treatments. Their mission is based on a patient-centred approach, guaranteeing high-quality care while contributing to the training of tomorrow's healthcare professionals.

OUR PARTNERS

WYSS CENTER

The Wyss Centre for Bio and Neuroengineering is a translational research institute dedicated to advancing neurotechnologies and biomedical solutions. By combining expertise in neuroscience, artificial intelligence and biomedical engineering, it develops innovative technologies to improve diagnosis, treatment and quality of life for patients with neurological disorders. Through an interdisciplinary approach and state-of-the-art infrastructure, the Wyss Centre accelerates the transition from scientific discoveries to clinical applications, in collaboration with researchers, academic institutions and industrial partners. Its commitment to innovation and cutting-edge research makes it a major player in the field of neurotechnology and the medicine of tomorrow.

h e p i a

Haute école du paysage, d'ingénierie et d'architecture de Genève

The Haute école du paysage, d'ingénierie et d'architecture de Genève (HEPIA) is an educational and applied research institution that plays a key role in developing innovative solutions for engineering, architecture and land management. As part of the network of universities of applied sciences in Western Switzerland (HES-SO), HEPIA offers practice-oriented courses that are closely linked to the professional world, thus promoting the employability of its graduates. Thanks to its laboratories and collaborations with industry and local authorities, it actively contributes to ecological transition, sustainable technologies and smart urban planning. With its interdisciplinary approach and regional roots, HEPIA is a key player in innovation for sustainable development, urban and landscape planning in the Lake Geneva area.

Governance

The Foundation Board is the supreme body of the FCBG. It is composed of representatives from UNIGE, EPFL, the Canton of Geneva and HUG.

The FCBG's CEO participates in meetings in an advisory capacity.

Members of the Foundation Board :

President	**Prof. Audrey Leuba**, Rector of UNIGE
Vice-President	**Prof. Anna Fontcuberta i Morral**, President of EPFL
	M. Robert Mardini, Chief Executive Officer of the HUG
	M. Daniel Loeffler, Deputy Secretary General DEE, Canton of Geneva

Members of the Bureau of the Foundation Board as of January 1, 2026:

Coordinator	**Dr. Nicolas Durand**, Chief Executive Officer of the FCBG
	M. Lionel Cau, Director of Operations, UNIGE Campus Biotech
	Dr. Danielle Desravines, Director of Operations, EPFL Geneva
	Prof. Antoine Geissbuhler, Dean of the Faculty of Medicine, HUG
	Prof. David Sander, President of the Academic Council 2026

Retrospective

2013

Creation of FCBG by EPFL and UNIGE. Arrival of the first research group (CISA).

2014

Launch of the Human Brain Project

2015

HUG joins FCBG, official inauguration of Campus Biotech, rollout of first neuroscience platforms

2016

Installation of HEPIA laboratories, inauguration of the Campus Biotech Innovation Park

2017

Launch of the Genome Center

2018

Campus Biotech becomes a key player in the Swiss Innovation Park (SIP WEST EPFL)

2019

Launch of the gene therapy platform







2020

Obtained a donation of CHF 20 million to purchase state-of-the-art functional imaging equipment (MEG & 7T MRI)

2021

Obtained a donation of CHF 36 million to set up an organoid platform

2022

Installation of Switzerland's first MEG and 7T MRI







2023

Partnership established with FONGIT

2024

Development of clinical activity on most platforms, launch of an outpatient clinic for the HUG

2025

Inauguration of the AI Hub (innovation in artificial intelligence applied to healthcare, health, and neurotechnologies)

Dr. Nicolas Durand (CEO), Ms. Isabelle Jeanclaude (HR & Facility Manager), Dr. Olivier Reynaud (Platforms Manager) et Ms. Sara Llort (CFO)

A DYNAMIC AND EFFECTIVE MANAGEMENT TEAM FOR THE CAMPUS BIOTECH GENEVA FOUNDATION

Management Team

The year 2025 was marked by the consolidation of the momentum begun the previous year and the affirmation of a governance approach resolutely focused on impact and performance. Under the leadership of Dr Nicolas Durand (Chief Executive Officer), the Management Team – comprising Sara Llort (Director of Administration & Finance), Dr Olivier Reynaud (Head of Platforms) and Isabelle Jeanclaude (Head of HR & Infrastructure) – continued to strengthen the Foundation's structure and strategy.

Beyond the optimization measures implemented in 2024, the focus in 2025 was on long-term structuring, professionalizing internal processes, and developing new growth drivers. In particular, the team worked to clarify strategic priorities, strengthen coordination between platforms, and improve the FCBG's external visibility among its institutional, academic, and industrial partners.

Particular attention has also been paid to financial sustainability, transparency of management mechanisms, and attractive framework conditions for researchers and technical teams. This integrated approach, combining rigorous management and scientific ambition, allows the Foundation to look ahead to the coming years with confidence.

Thanks to a united, complementary, and committed management team, the FCBG is continuing its development based on clear, agile, and excellence-oriented governance, serving neuroscience and neurotechnology research.

« In 2025, our ambition was to consolidate our achievements, clarify our strategic priorities, and strengthen our impact. More than just a center of excellence, the FCBG must be a catalyst for innovation, capable of transforming cutting-edge research into sustainable value for society. »

Dr. Nicolas Durand, Chief Executive Officer, FCBG



Prof. Olaf Blanke, Prof. Stéphanie Lacour, Prof. David Sander, Prof. Camilla Bellone and Prof. Antoine Geissbuhler

Academic Council

AN ACADEMIC COUNCIL AT THE HEART OF THE FCBG'S SCIENTIFIC STRATEGY

In 2025, the Academic Council played a decisive role in defining the FCBG's strategic directions for the coming years. Following its establishment in 2024, the past year marked a key milestone with the development of a structuring vision entitled «The Neuro Continuum: From Brain Mechanisms to AI-guided therapies.»

Under the chairmanship of Prof. Stéphanie Lacour, the Council conducted an in-depth review aimed at coherently and ambitiously articulating the Campus's entire scientific value chain: from understanding the fundamental mechanisms of the brain to developing therapies guided by artificial intelligence. This integrative approach positions the FCBG as a player capable of linking fundamental research, advanced technologies, and clinical applications with a strong societal impact.

Regular exchanges between representatives of partner institutions and the management team have made it possible to align this strategy with the Campus's existing strengths, identify priority areas for investment, and strengthen the complementarity of technological platforms. Particular attention has been paid to data integration, interdisciplinarity, and the translational potential of the projects supported.

« To maintain a leading role in neuroscience and neuroengineering, the Fondation Campus Biotech Geneva must leverage the complementarity of its partner institutions, pursue clear scientific priorities, and maintain a strong focus on impact. In this context, the Academic Council plays a central role in guiding the scientific direction and ensuring alignment across stakeholders. Its mission is to provide oversight and strategic input, ensuring clarity, consistency, and a strong strategic perspective in the development and implementation of the Foundation's activities.

Prof. Stéphanie Lacour,
President of the Academic Council 2025, FCBG

Platform Advisory Committees (PACs)

Each FCBG platform has its own Platform Advisory Committee (PAC), which is a scientific committee created to provide specific academic insight for each platform. Composed of key members of the community (appointed by the Academic Council) and the platform manager, the PAC meets monthly to contribute its scientific and technological expertise.

The PACs are responsible for identifying and prioritizing the needs of their platform, particularly with regard to equipment renewal, and defining a development strategy.

In addition, it stimulates synergies within the scientific community and promotes the platform both internally and externally.

For all strategic or budgetary decisions, the PACs submit their recommendations to the Academic Council and, if necessary, to the Management Team and the Foundation Council. These committees, organized jointly by the Platform Manager, Dr. Olivier Reynaud, and the managers of each platform, thus play a central role in the development and optimization of the FCBG platforms.



Academic members of the Magnetic Resonance Imaging Platform (MRI) PAC:

Prof. Frédéric Grouiller	UNIGE/CIBM
Prof. Patrik Vuilleumier	UNIGE/CIBM
Prof. Valentina Borghesani	UNIGE
Prof. Olaf Blanke	EPFL
Prof. Dimitri Van De Ville	EPFL/CIBM
Prof. Andreas Kleinschmidt	HUG
Prof. Jean-Paul Vallée	HUG/CIBM
Prof. Karl-Olof Lovblad	HUG
Prof. Dimitrios Karampinos	EPFL/CIBM

cademic members of the Magneto-, Electro-Encephalography and Neuromodulation Platform (MEG) PAC:

Prof. Friedhelm Hummel	EPFL
Prof. Alexis Hervais-Adelman	UNIGE
Prof. Adrian Guggisberg	HUG

Academic members of the Preclinical Neuroscience Platform (PNP) PAC:

Prof. Grégoire Courtine	EPFL
Prof. Denis Jabaudon	UNIGE
Dr. Bernard Schneider	EPFL

Academic members of the Virtual Reality and Digital Engineering Platform (VRD) PAC:

Prof. Alexander Mathis	EPFL
Prof. Daphne Bavelier	UNIGE
Dr. Oliver Kannapé	HUG

Academic members of the Human Cellular Neuroscience Platform (HCNP) PAC:

Prof. Pierre Magistretti	EPFL
Prof. Fides Zenk	EPFL
Prof. Denis Jabaudon	UNIGE

Academic members of the Neural Microsystems Platform (NMP) PAC:

Prof. Stéphanie Lacour	EPFL
Dr. Didier Ferrere	UNIGE

Academic members of the Clinical and Sleep Research Platform (CSR) PAC:

Prof. Friedhelm Hummel	EPFL
Prof. Sophie Schwartz	UNIGE
Prof. Indrit Bègue	HUG

FCBG partners

STRATEGIC PARTNERSHIPS FOR EXCELLENCE IN INNOVATION

Since its creation, the FCBG has been built on a unique collaborative model, bringing together academic institutions, hospitals, research centers, and industry players. In 2025, these partnerships continued to intensify, strengthening the FCBG's role as a convergence platform for translational research and technological innovation.

The FCBG expresses its deep gratitude to its partners and donors for their commitment and trust, which make our training and innovation activities possible. Some have been with us since the Foundation was created, and we sincerely thank them for their loyalty.

campus biotech

EPFL

UNIVERSITÉ DE GENÈVE

HUG Hôpitaux Universitaires Genève

REPUBLIQUE ET CANTON DE GENEVE

WYSS CENTER

h e p i a
Haute école du paysage, d'ingénierie et d'architecture de Genève

NeuroNA

FONGIT

fb fondation bertarelli

CIBM Center for Biomedical Imaging

nccr evolving language

SWITZERLAND INNOVATION

newrest

gesda

BioAlps

GENILEM

OTHER ENTITIES PRESENT ON THE CAMPUS BIOTECH SITE

Alongside FCBG, Campus Biotech hosts a dynamic ecosystem bringing together academic, clinical, industrial, and institutional players. They collaborate and coexist with start-ups, innovative companies, and international organizations, creating an environment conducive to innovation, interdisciplinary research, and technology transfer.

Access Accelerated	Aga Khan Development Network	Agora Care	Amazentis
André Roland	ARB Biotech	Artiria Medical	Biostime Institute for Nutrition and Care
BioXpess Therapeutics	Bridges to development	BrainQuant	BrainScape
CEDAM	Climb Ventures	Concept Foundation	Cosmovici Intellectual Property
CyberPeace Institute	DBS System	Dandelion Science	DataFlight Solutions
dEEGtal	DiaAIza	DONA Fondation	Dure Technologies
Earlysight	Ebamed	EspeRare	Forethought Access
Genegis BioLab	Gliapharm	Goodwall	HC2 Health Care
High Lantern Group	HMCare	IFPMA - International Federation of Pharmaceutical Manufactures & Associations	
IMSG - International Management School Geneva		Incite Medical Eng	Iot Lab
Ionctura	iRhytm	ISA-Lex Avocats	MedC Partners
Centre Synapsy (NCCR Synapsy)	Neurosoft Bioelectronics	Neurosterix / Addex	Octave Biotech
OneDoc	Orion Biotechnology Switzerland	Phasis	Regdata
Release Therapeutics (MaxiVax)	Relief Therapeutics	Rodanotech	SCIENTIS
Stalicla	Trust Village	Wecan Group	World Connect

The Magnetic Resonance Imaging (MRI) platform

PRESENTATION

MRI is an essential tool for neuroscience research, enabling anatomical, functional, and brain connectivity imaging with millimeter precision. Managed by Dr. Roberto Martuzzi, the MRI platform specializes in high-risk, high-impact MRI studies, integrating advanced technological, methodological, and analytical components.

KEY FEATURES

The MRI platform houses one of the few latest-generation 7 Tesla MRI scanners in Europe, enabling cutting-edge research in the fields of technical development, neuroscience, and clinical research. The platform integrates MRI data with EEG, virtual reality, electrical or magnetic stimulation, and biomarker analysis, thereby maximizing research potential.

Key equipment

Siemens Healthineers MAGNETOM Prisma 3T MRI

Siemens Healthineers MAGNETOM Terra.X 7T MRI

Motion capture, virtual reality, and non-invasive brain stimulation systems compatible with 3T MRI



KEY FIGURES FOR 2025

1st

Siemens Healthineers MAGNETOM Terra.X scanner in the world

25

peer-reviewed publications in 2025 (scientific journals)

Over 2,600 hours

of MRI scans in 2025

2 days/week

of clinical activity in ultra-high field MRI supported by the HUG

Highlights in 2025

- The Siemens Healthineers MAGNETOM Terra.X 7 Tesla MRI scanner incorporates AI-assisted image reconstruction for improved accuracy and resolution.
- The partnership with the HUG Diagnostic Department has been strengthened, enabling an increase in the number of patients examined by the HUG.
- The partnership with the Center for Biomedical Imaging (CIBM) has been strengthened, enabling technological developments in ultra-high field MRI imaging.
- The number of research groups using the MRI platform increased in 2025. Currently, users are mainly affiliated with four different academic institutions and three industrial partners.

Outlook

The platform aims to strengthen collaboration with other platforms and improve the integration of EEG, VR, and neuromodulation technologies with 3T and 7T MRI.

« The FCBG MRI platform promotes close collaboration, particularly with the HUG and the CIBM, by utilizing complementary MRI equipment, including the 7 Tesla MRI scanner, to advance clinical and translational research. These partnerships, along with strong synergies with other local platforms, accelerate innovation and strengthen patient-centered research. »

Prof. Frédéric Grouiller,
Head of the CIBM MRI HUG-UNIGE section and President of the MRI PAC



M/EEG & Neuromod (MEG) platform

PRESENTATION

Managed by Dr. Gwénaël Birot, the M/EEG & Neuromod platform provides researchers with equipment and expertise in electroencephalography (EEG), magnetoencephalography (MEG), and neuromodulation. EEG and MEG are key neuroimaging techniques that can track brain activity on a millisecond scale, making them ideal for studying rapid brain processes. Neuromodulation uses electrical (TES) or magnetic (TMS) stimulation to non-invasively modulate brain activity, particularly in psychiatry to study and treat disorders such as depression and schizophrenia.

KEY FEATURES

- The only MEG system in Switzerland.
- Multimodal integration with other platforms:
  - Simultaneous TMS/fMRI, TACS/fMRI, EEG/VR, and EEG/Neuromodulation.
- Expertise in real-time EEG for brain-computer interface (BCI) and neurofeedback protocols.





KEY FIGURES FOR 2025

Key equipment

MEGIN Triux neo MEG system

7 EEG systems
with ultra-high-density helmets

3 TES systems
compatible with MRI and EEG

3 TMS systems,
including TMS-MRI and rTMS for treatments

8
experimental cabins

Physiological recording devices (eye tracking, respiration, heart rate, etc.)

+10,000 hours
of equipment use

18
peer-reviewed publications in 2025 (scientific journals)

67 projects
from 38 research groups and 6+ academic partners

Highlights in 2025

- Start of MEG acquisitions on pediatric populations.
- Development of the very first temporal interference stimulation (tTIS) protocols combined with MEG, MRI, or EEG acquisitions.
- Major collaboration with the HUG on a clinical trial using transcranial magnetic stimulation technologies.

Outlook

The platform plans to adopt and integrate new technologies such as temporal interference stimulation, ultrasound, OPM-MEG, and robotic TMS for increased precision. It also aims to expand its services to international researchers and private companies.

« The FCBG's MEEG-NMOD platform offers exceptional infrastructure and active practical support for cognitive neuroscience research requiring cutting-edge techniques. Thanks to the platform team, we can launch studies efficiently and effectively, even for complex projects involving multiple phases and instruments. »

Prof. Alexis Hervais-Adelman,
Faculty of Medicine, University of Geneva, and member of the MEG PAC



Preclinical Neuroscience Platform (PNP)

PRESENTATION

Founded in 2016, the Preclinical Neuroscience Platform (PNP) offers a wide range of in vivo and ex vivo services and benefits from the dynamic research environment provided by Campus Biotech. The platform provides efficient facilities, appropriate equipment, and adequate support dedicated to neuroscience and neurodevice research on rodent models. Approximately 2,000 m², spread over three floors, are dedicated to neuroscience research, with a team of eight qualified professionals supporting the research teams.

The platform is divided into two main areas:

- Experimental areas (operating rooms and experimental rooms).
- Laboratories, offering three facilities for the preparation, processing, and analysis of tissues or cells. The laboratories have areas dedicated to histology, molecular biology, and cell culture.

KEY FEATURES

- State-of-the-art infrastructure and shared spaces equipped with key scientific tools.
- Preclinical studies and ex vivo analyses within a single platform.
- Support for researchers from a dedicated support team.

Highlights in 2025

- Implementation of the new animal welfare ordinance
- Development of new collaborations and services
- Arrival of Professor Valerio Zerbi (UNIGE) at Campus Biotech

Outlook

Expansion of experimentation and histology services to better support researchers.

Active support for the Lighthouse Project led by the Wyss Center, notably in collaboration with EPFL, UNIGE, and HUG. This project aims to develop new technologies to treat neurological and mental health disorders through AI-guided neuromodulation.

« The FCBG's scientific platforms offer efficient services and access to cutting-edge technologies that enable innovative research in translational neuroscience. The collaborative inter-institutional environment of the platforms at Campus Biotech provides researchers with shared resources that accelerate scientific advances and innovation. We are extremely grateful for this support, which plays a crucial role in the scientific progress of our laboratories.»

Dr. Bernard Schneider,
Head of the
Bertarelli Gene Therapy Platform (EPFL)

KEY FIGURES FOR 2025

PNP surface
1,870 m²
experimental areas : 1,640 m²,
laboratories : 230 m²

15 research groups
and over 100 users

130
major pieces of equipment

26 publications
since 2023, including several studies in prestigious scientific journals in 2025, for example:

- Soriano et al (Nature, 2025). A neuronal architecture underlying autonomic dysreflexia.
- Squair et al (Science 2025). Unbiased discovery of neuronal architectures.



Virtual Reality and Digital Engineering Platform (VRD)

PRESENTATION

Digital technologies offer versatile tools for conducting realistic, safe, and reproducible experiments. The VRD platform supports the scientific community by creating immersive content and customized 3D applications. While virtual reality remains our core business, particularly for MRI and EEG studies, our activities have expanded to include serious games for computers and mobile devices. This multi-platform approach offers accessible solutions that bridge the gap between research and clinical applications, accelerating innovation for the entire scientific community.

KEY FEATURES

- Team members have a wide range of skills, including XR (virtual, augmented, and mixed reality) development on different operating systems (Windows, Mac, Linux, Android, iPhone), as well as motion capture and the use of various sensors.
- Collaboration with other platforms facilitates the implementation of multidisciplinary projects integrating brain imaging technologies (MRI, EEG, MEG, etc.).
- Interactions and proximity with scientists, professors, and students enable a rapid understanding of the specific needs and challenges of each study.

Faits marquants en 2025

- Creation of an MRI environment in a virtual world and the ability to view and move an avatar's body in real time.
- Development of EyeTracking in the MRI-compatible VR headset for interactions and movement.
- Technical demonstration of simultaneous acquisition of EEG + VR + Motion Capture + real-time visualization of the participant's heart rate.

KEY FIGURES AND PROJECTS IN 2025

Expansion of the application catalog to
44 delivered projects

3 peer-reviewed publications
in 2025 (scientific journals)

14 projects developed
during the year, including:

EcoRescue is a serious game developed in collaboration with Naïma Graddi, Professor Daphne Bavelier (UNIGE), and Professor Swann Pichon (HEdS). Set in six galaxies affected by space pollution, the app tasks players with restoring planetary ecosystems through specialized missions. For example, capturing butterflies stimulates vegetation growth, while recruiting pilots facilitates environmental cleanup. The game features a dynamic difficulty system that adapts to players' performance in order to maintain their engagement. This project is part of a larger study on adolescents.

The **Play2BEAPI** research project aims to validate a new assessment tool designed to measure upper limb movements in children with neuromotor disorders. It combines an instrumented aeroplane game with 3D motion analysis. During a gaming session, the child performs a series of 'flight missions' with both hands. Each mission assesses specific movements, such as elbow extension or shoulder elevation, in an immersive environment that encourages spontaneity. The capture of detailed kinematic data thus makes it possible to precisely characterise motor deficits in order to optimise therapeutic interventions.

Outlook

- Integration of Artificial Intelligence into virtual content creation.
- Development of virtual reality tools compatible with ultra-high field 7 Tesla MRI.

« Virtual reality is a fantastic tool for understanding human behavior, from perception to memory. »

Prof. Alexander Mathis, EPFL

« The Virtual Reality and Digital Engineering platform allows us to create experiences that are closer to everyday reality, while providing accurate measurements of brain functions, a crucial advance in our understanding of the brain and behavior. »

Prof. Daphné Bavelier, UNIGE



Neurona Human Cellular Neuroscience Platform (HCNP)

PRESENTATION

Led by Dr. Théo Ribierre and funded by the Geneva-based NeuroNA Foundation, the Human Cellular Neuroscience Platform (HCNP) stands out for its unique mission and capabilities. It provides state-of-the-art equipment for the culture, genomic editing and differentiation of 3D human brain organoids, as well as for the collection, handling and biobanking of human brain samples. Advanced analytical tools enable multimodal characterisation of human samples (genetics, transcriptomics, microscopy and electrophysiology).

The HCNP offers its services to the academic and entrepreneurial community and assists researchers in drafting funding applications and ethical protocols for biobanks. The infrastructure is NORMA-certified by the Swiss Biobanking Platform.

« Platforms play a key role in advancing our science. From cellular neuroscience to human imaging, a wide range of equipment is available. The equipment is important, but it is worthless without the expertise that goes with it. This expertise is also available on site, enabling us to anticipate and make the right decisions. »

Prof. Denis Jabaudon, UNIGE

KEY FIGURES

18
projects in progress

1 grant
obtained as a co-investigator

2 scientific publications

Key equipment

Vizgen MERSCOPE
spatial transcriptomics

Nikon AXR
confocal microscope with incubation chamber

10X Genomics Chromium X
microfluidic device for high-throughput single-cell transcriptomics

3Brain HYPERCAM Alpha
high-density electrophysiological measurements

Becton Dickinson FACS Melody
cell sorting device

Specialized equipment for stem cell culture, tissue preparation, molecular biology, and biobanking

KEY FEATURES

- State-of-the-art equipment for conducting innovative research projects in human cellular neuroscience, from cell culture to final analysis.
- Dedicated staff providing expertise in each key technique, with support ranging from project writing to molecular biology, cell reprogramming, cell cultures, microscopy, and biobanking.
- Customized services, with priority given to academic laboratories.

Highlights in 2025

- Relocation of a facility to meet stricter standards for cross-contamination prevention:
  - Creation of separate rooms for pre- and post-amplification phases.
- Organization of three multi-day technology workshops:
  - Manipulation of human stem cells (with STEMCELL Technologies).
  - Automation of acquisition and analysis for bioimaging (with Nikon).
  - High-density recordings and analyses using multi-electrode arrays of human brain organoids (with 3Brain).
- Key partnership with the neurosurgery and pathology departments at HUG for the development of an optimized pipeline for the culture of human organotypic brain slices.

Outlook

- Exploration of robotic automation for lengthy experimental steps.
- Creation of an integrated preclinical technology center dedicated to human cellular neuroscience, offering customized services in genetics, transcriptomics, and electrophysiology on brain models derived from human tissue.

Neural Micro-Systems Platform (NMP)



PRESENTATION

Created in 2015 within the Wyss Centre and transferred to the FCBG in 2021, the Neural Micro-Systems Platform (NMP) specialises in the development of portable and implantable neurotechnologies. Managed by Michaël Stoeckel, the NMP has a clean room of approximately 120m². The platform brings together experts in engineering, life sciences and medical sciences to design advanced neurotechnology solutions. The NMP focuses on improving biointegration, bidirectional modalities and the spatio-temporal resolution of devices, thereby addressing the challenges associated with clinical demonstration and large-scale manufacturing.

KEY FEATURES

NMP excels in the development of portable and implantable devices offering improved biointegration and excellent performance. While many innovations target neuroscience research (e.g., conformable epiretinal implants, e-dura, flexible ECoGs), few reach medical applications; NMP fills this gap by supporting clinical demonstration.

Highlights 2025

- Installation and qualification of the Coat-X CXC-20 multi-layer deposition tool. The equipment has successfully passed all qualification tests and is now fully operational.
- Presentation of the NMP Platform at the EPFL CMi Day exhibition (May 2025).
- The start-up Neurovia Bioelectronics begins operations on the NMP Platform (November 2025).



KEY FIGURES

key equipment

120 m² cleanroom (ISO7, class 10,000)

Laser micromachining, Heidelberg mask-less aligner, Alliance Concept Sputter and Evaporator, Corial Etcher, Hitachi environmental SEM, Nanolab

New Coat-X CXC-20 multi-layer deposition equipment

System designed to create hermetic multilayer barrier coatings composed of thin films of parylene and ceramic.

Atomic Layer Deposition (ALD) module for the precise growth of ultra-thin ceramic interlayers.

Chemical vapor deposition (CVD) module for high-quality parylene thin films.

Technology particularly suited to protecting active implantable medical devices (AIMDs) against damage caused by corrosion.

Improvement of long-term in vivo durability, biocompatibility, and mechanical strength of all medical devices.

Outlook

- Participation in the Swiss Microscopy Facility Day organised by the Wyss Centre at Campus Biotech.
- For the eighth consecutive year, the NMP Platform easily passed its qualification tests (Particle + Micro-burden).

« The Neural Micro-Systems Platform (NMP) offers a unique environment where microfabrication, thin-film technology, and neural implant development intersect, bridging the gap between fundamental research and translational manufacturing. With its expertise in polymer-based microfabrication, the NMP enables new approaches to neural interface design, supporting both scientific discovery and technological advancement in neurotechnology. »

Prof. Stéphanie Lacour (EPFL), Member of the PAC of the NMP



Clinical and Sleep Research Platform (CSR)

PRESENTATION

Co-directed by Dr Virginie Sterpenich and Dr Kinga Igloi, the Clinical and Sleep Research Platform (CSR) offers a state-of-the-art environment dedicated to clinical and sleep research.

It comprises eight private rooms for behavioural testing, neuropsychological interviews and clinical assessments, in a secure and confidential setting for volunteers and patients, including the HUG outpatient clinic. Two specialised rooms are equipped with six synchronised cameras for analysing movements and facial expressions, facilitating non-invasive digital phenotyping of psychiatric and neurological disorders. Neurological assessments are available for children and adults.

The CSR also has a level 2 (P2) safety laboratory for blood and saliva analysis, enabling the measurement of biomarkers (hormonal and genetic) to complement neurophysiological and neuroimaging data. Expertise is offered for study design, data management and multimodal integration.

Finally, three sleep chambers, equipped for polysomnography and compatible with several EEG systems, enable multidisciplinary investigations of brain function before, during and after sleep.

KEY FEATURES

- The only sleep research platform in French-speaking Switzerland, distinguished by its multimodal and multi-platform approach.
- On-site accommodation is provided in three single rooms, all equipped with an EEG system and a controlled olfactory simulation device.
- An advanced system of synchronised cameras enables AI-based assessment and analysis of certain psychiatric and neurological disorders.

Highlights in 2025

- Launch and active use of the new digital phenotyping service, with a project now using rooms equipped with cameras.
- High occupancy rate of clinical rooms and close collaboration with the outpatient clinic.
- Growing demand and use of the biomarker analysis service.

Outlook

- Continuous improvement of internal camera recording software.
- Development of a structured AI-based video analysis pipeline to classify and characterise neurological and psychiatric populations.
- Expansion of the biomarker analysis catalogue through the implementation of new laboratory techniques.
- Refurbishment of the sleep laboratory to enable multiple studies to be conducted simultaneously.

KEY FIGURES

39+
research projects, including 10 related to the biomarker service

110+
full nights and 60+ naps with polysomnographic recordings

+2,900 hours
of use of the sleeping rooms

+6,880 hours
of behavioural experiments

5 peer-reviewed publications
in 2025 (scientific journals)

« The Clinical and Sleep Research Platform provides exceptional support for clinical research and fundamental studies in neuroscience. It manages sleep monitoring, comprehensive clinical assessments with extensive video recordings, and biomarker analysis. Thanks to its state-of-the-art equipment and expert staff, it facilitates the smooth execution of research projects, including randomised clinical trials. »

Prof. Indrit Bègue, HUG



Le Health 2030 Genome Center (GC)

PRESENTATION

Created in 2017 by the Health 2030 initiative, the Genome Centre (GC) promotes genomic research and medicine in Switzerland. The GC offers genomic data generation, analysis and management services to the Swiss research and clinical community. Since 2022, it has played a key role in national initiatives such as the Swiss Personalised Health Network (SPHN) and the ETH PHRT programmes. The Genome Centre comprises two platforms: the DNA sequencing platform (DSP) and the data analysis and interpretation platform (DAIP).



KEY FEATURES

The Genome Centre offers ISO 15189-accredited clinical-grade services, ensuring reliable data for healthcare. It stands out for its expertise in large-scale genomic projects, providing rapid information for intensive care, precision oncology and population genomics.

Highlights in 2025

- ISO 15189 accreditation (medical biology laboratory for testing in the field of human genetics) for WGS, WES and RNA-seq services.
- Completion of the pilot phase of the 'Genome of Switzerland' project, led by EPFL and funded by ETH PHRT, which aims to provide the first nationally representative genomic reference dataset in Switzerland.
- Strengthening of collaborations with Swiss university hospitals on projects in various clinical areas, such as precision oncology, rare diseases, pharmacogenomics and complex diseases.
- Genomic partner in the SPHN FEGA project, which aims to provide a secure repository for archiving the human genome generated by researchers in Switzerland.

Outlook

- Restructuring of the Platform under new governance to make it a national infrastructure that meets Switzerland's needs in terms of translational and population genomics.
- Upgrading of the Genomics Centre's IT and data generation systems to provide: 1) flexible, cost-effective and state-of-the-art sequencing solutions; 2) additional types of omics data (long-read sequencing, methylation) that will be clinically useful in the coming years; 3) an optimal infrastructure for computing, storing and exchanging genomic data.
- Extension of the current pilot phase of Genome Switzerland to sequence 15,000 population samples in Switzerland. The aim is therefore to build a dataset of national importance and facilitate the use of genomic resources within the Swiss Federated Genomic Network.
- Evaluation, implementation and accreditation of new sequencing-based tests with clinical utility; facilitation of the integration of genomic and other omics data into clinical workflows.

« At the Genome Centre, we have taken on the responsibility of providing personalised healthcare to Swiss citizens through national initiatives in genomics and in collaboration with the Genome of Europe project. »

Prof. Alexandre Reymond, Director of the Genome Centre since November 2024 and professor of human genetics at the University of Lausanne



HUG Outpatient Neuroclinic

ADVANCING BRAIN HEALTH THROUGH INNOVATION

In 2025, the Neurocenter at Geneva University Hospitals (HUG) continued the pilot phase of its outpatient clinic dedicated to brain and mental health at Campus Biotech. This consolidation phase made it possible to refine care pathways, strengthen clinical and academic synergies, and confirm the relevance of an integrated model at the heart of a research ecosystem. The project continues to be carried out in close collaboration with the Departments of Clinical Neuroscience and Psychiatry, headed respectively by Prof. Karl Schaller and Prof. Stefan Kaiser.

Hôpitaux Universitaires Genève | NEUROCENTRE

This initiative illustrates the HUG's commitment to improving care and stimulating innovation in neurological diseases, neurotrauma, and brain health.

https://www.hug.ch/en/neurocentre/outpatient-clinic-brain-and-mental-health

The clinic initially focuses on cognitive and motivational deficits, which are very common in traumatic brain injuries and psychiatric disorders. By integrating the latest advances in research, innovation, and patient care, this clinic aims to improve outcomes for people facing complex brain health challenges. It promotes synergies between research and clinical care, accelerating the transformation of scientific discoveries into optimized therapeutic strategies.



ACTIVITIES

This state-of-the-art infrastructure was relocated in 2025 to the entrance of the Biotech Campus, alongside the AI Hub, thereby enhancing visibility and strategic synergies at the heart of the site. Neurological, neuropsychological, psychiatric, and neurosurgical examinations are carried out on site by HUG doctors in recently renovated consultation rooms. These assessments are often supplemented by MRI scans performed on neighboring imaging platforms, in particular using the latest-generation 7 Tesla MRI scanner, which offers an unprecedented level of cerebral detail for the Geneva clinical population.

The main objective of this multidisciplinary consultation unit is to provide specialized follow-up care for patients with persistent cognitive and motivational deficits.

Already incorporating its first research projects, the HUG outpatient clinic began with an innovative clinical trial based in Geneva, aimed at improving negative social symptoms in psychiatric patients. This study, which was awarded the Leenards Foundation Prize in 2023, applies the latest advances in neurotechnology and non-invasive brain stimulation, offering direct benefits for patients' comfort and quality of life.

IMPACT AND VISION

This initiative expands access to clinical care while advancing translational research in neurotechnologies, cognitive sciences, and therapies developed at Campus Biotech. Outpatient consultation strengthens Geneva's position as a global leader in neuroscience and healthcare innovation by fostering collaboration between researchers, clinicians, and technology experts to improve patient outcomes.



Our services

SERVICES DEDICATED TO A DYNAMIC AND INNOVATIVE COMMUNITY

The FCBG provides its researchers, employees, and partners with a comprehensive range of services designed to facilitate scientific work, encourage innovation, and improve well-being on campus. In 2025, we continued to improve our services in order to meet the evolving needs of our users and enhance the long-term appeal of the site.

EVENTS: A MEETING PLACE FOR SCIENCE AND INNOVATION

Campus Biotech is a hub for exchange and collaboration, hosting more than 150 scientific, academic, and industrial events each year. Conferences, workshops, and seminars are organized to promote dialogue between researchers, startups, and companies. Thanks to modern facilities—conference rooms, an auditorium, and reception areas—event planning is made easy, ensuring an environment conducive to knowledge sharing and scientific advancement.

FCBG'S SUPPORT FOR THE CENTER FOR ARTIFICIAL INTELLIGENCE APPLIED TO HEALTHCARE, HEALTH, AND NEUROTECHNOLOGIES

On December 4, 2025, Geneva inaugurated its first Artificial Intelligence in Healthcare Hub at Campus Biotech. The Foundation was delighted to be closely involved in setting up this strategic hub, supporting its integration into the Campus's scientific and technological ecosystem and facilitating synergies between academic, clinical, and technological partners.

Operated by Geneva University Hospitals, in partnership with the Wyss Center and the Department of Health and Mobility (DSM) of the Canton of Geneva, the AI Hub aims to accelerate the translation of artificial intelligence research into clinical practice, particularly for neurological and psychiatric diseases.

Located on nearly 1,000 m² at the entrance to the Campus Biotech, it brings together clinicians, researchers, and AI specialists in a shared space dedicated to transforming diagnosis, care, and neurotechnologies through data-driven approaches. As the operator of the Campus's technology platforms, FCBG has helped

to create the conditions conducive to this convergence by providing an integrated environment combining state-of-the-art infrastructure, multidisciplinary expertise, and clinical proximity.

The AI Hub is structured around four strategic missions: specialized care and consultations, translational research, integration of AI into hospital processes, and training with open dialogue on ethical and societal issues. The teams will offer consultations dedicated to brain and mental health, including epilepsy, stroke, depression, and sleep disorders, with access to innovative diagnostic and therapeutic strategies as well as clinical trials.

In research, AI-guided neuromodulation projects and the development of neurotechnology start-ups will strengthen the continuum between scientific discovery and clinical application. Through its unifying role and strategic vision, the FCBG is delighted to have contributed to the emergence of this hub, which reinforces Geneva's position as a major player in innovation in health and neurotechnologies.

IT: cutting-edge technological support

The FCBG IT department provides its users with a reliable, high-performance, and secure infrastructure. It guarantees access to the digital tools needed for research projects, offers responsive technical support, and ensures data protection. An information systems security policy was implemented in 2025 to support the growth of scientific platforms and strengthen cybersecurity.



Workshop (mechanical workshop): from idea to completion

The FCBG mechanical workshop provides a manufacturing and machining space for the design of prototypes and research devices. Thanks to state-of-the-art equipment (milling machines, lathes, laser cutting, etc.), researchers and engineers can design and refine their projects with the support of mechanical engineering experts. This service plays a key role in the development of measurement benches for various research projects.

3D printing and prototyping: accelerating innovation

In collaboration with HEPIA, the design and manufacturing service offers access to 3D printing and rapid prototyping, enabling researchers and entrepreneurs to quickly bring their ideas to life. FCBG has a fleet of 3D printers capable of working with various materials (plastic, resin, metal) to produce models, experimental devices, and functional prototypes.

Daycare: balancing work and family life

To support researchers and employees with children, a modern and welcoming daycare center is available on the Campus Biotech site. It offers a safe and stimulating environment for children, with hours tailored to the needs of parents working on site and in the surrounding area. This service helps improve work-life balance and enhances the appeal of the Campus.



Fitness: well-being and performance every day

Employee well-being is a priority for FCBG. The fitness center offers a range of equipment to promote health and performance. Whether for a quick workout or a more intense session, this space contributes to the quality of life on site and encourages a balanced approach to work and physical well-being.



Infrastructure management: an optimized environment

The infrastructure management department ensures the smooth running and maintenance of Campus Biotech's buildings, laboratories, and common areas. It manages resources, energy, and technical equipment efficiently, guaranteeing an optimal working environment for researchers and companies. In 2025, several improvements were implemented to optimize energy consumption and reduce the site's carbon footprint.

Infirmary: fast and effective care

The Campus Biotech infirmary provides rapid medical care for employees and visitors. Whether for first aid, health advice, or minor emergency management, this service ensures a safer and more peaceful working environment.



Catering: Newrest treats us to a feast

In 2025, Newrest continued its commitment to providing high-quality catering services to its community. Building on its success since its arrival, Newrest continues to offer a variety of tasty dishes every day, made from fresh, local ingredients, in a responsible and sustainable manner. Thanks to its varied, balanced cuisine that caters to everyone's preferences and needs, the Campus restaurant is more than ever a central hub for socializing, interaction, and well-being at the heart of campus life.

2025: A YEAR OF SCIENTIFIC BREAKTHROUGHS AND TECHNOLOGICAL INNOVATIONS

Research and Innovation

In 2025, the Foundation continued its drive for excellence, with significant new scientific advances leading to numerous high-level publications and groundbreaking technological developments. Supported by cutting-edge infrastructure and ever closer collaboration between neuroscientists, engineers, and clinicians, these achievements have consolidated and expanded the fields of exploration in neurotechnology, advanced imaging, and digital health.

Prof. Mackenzie Mathis	SGV Award
Prof. Nako Nakatsuka	Ruzicka Award & ERC Starting Grant
Prof. Felix Kurz	FNS Grant
Prof. Daniel Wenz	FNS Grant
Prof. Pierre Magistretti	BioAlps Academy Award
Prof. Antoine Geissbuhler	François Grémy Award of Excellence Award
Prof. Alexandre Pouget	Swartz Award
Prof. Fides Zenk	Swiss 3RCC Award
Quentin Praz	Alumni HES-SO Award

« The Academic Council helps to harness the tremendous potential offered by the FCBG to develop research initiatives bringing together several institutions and various disciplines at Campus Biotech. »

— Prof. David Sander, Director of CISA, UNIGE, and President of the Academic Council in 2026

Unraveling the metabolic and neurovascular time scales underlying cognitive processes

A study conducted by Prof. Dimitri Van De Ville's group at EPFL, published in PNAS, shows how the brain balances stability and flexibility to adapt to a changing environment. By combining computational modeling and neural recordings, the researchers reveal that brain circuits dynamically adjust their activity: they stabilize useful representations while remaining capable of rapidly integrating new information. This balancing mechanism enables efficient learning without loss of acquired knowledge, shedding light on the neural basis of adaptation and decision-making.

https://doi.org/10.1073/pnas.2506513122

An implantable system for restoring hemodynamic stability after spinal cord injury

The study conducted by Prof. Grégoire Courtine's group at EPFL, published in Nature Medicine, shows that deep brain stimulation targeting the hypothalamus can restore walking ability in the long term after partial spinal cord injury. After promising results in animals, two patients regained sufficient voluntary control to walk without assistance and climb stairs. Beyond the immediate effects, persistent improvements were observed after stimulation was stopped, paving the way for new neuromodulatory therapies.

https://doi.org/10.1038/s41591-025-03614-w

Regional differences in progenitor metabolism modulate brain growth during development

A study conducted by Prof. Denis Jabaudon's group at UNIGE, published in Cell, reveals how large-scale neural dynamics enable the brain to integrate sensory information, memory, and goals to guide behavior. By combining high-resolution recordings, computational analyses, and targeted circuit manipulation, the authors identify coordinated activity patterns that support flexible decision-making. These results propose a framework linking cellular organization, distributed networks, and complex cognitive functions.

https://doi.org/10.1016/j.cell.2025.04.003

A map of neural activity throughout the brain during complex behavior

Published in Nature, this important article, of which Prof. Alexandre Pouget of UNIGE is one of the main authors, highlights a key molecular mechanism regulating the organization and plasticity of brain circuits. Using approaches combining genetics, imaging, and functional analyses, the researchers show how precise interactions between cell types shape the activity of neural networks and influence behavior. This work sheds light on the biological basis of neurological disorders and opens up new perspectives for targeted therapeutic interventions.

https://doi.org/10.1038/s41586-025-09235-0

Epidural stimulation and motor recovery in spinal cord cone lesions

A study conducted by Prof. Silvestro Micera's group at EPFL has been published in Cell Reports Medicine. This article presents an innovative approach combining multi-omic analyses, clinical data, and computational modeling to better stratify patients and predict disease progression. The researchers identify robust biomarkers associated with clinical trajectories and demonstrate the potential of these signatures to guide personalized interventions. These results reinforce the integration of precision medicine into clinical practice.

https://doi.org/10.1016/j.medj.2025.100706

Photo credit: Martial Trezzini / Keystone

Strategic innovation



THE BIOTECH CAMPUS AS A KEY INFRASTRUCTURE OF THE CANTONAL INNOVATION MASTER PLAN, CATALYZING SCIENTIFIC TRANSLATION, THE GROWTH OF START-UPS, AND GENEVA'S INTERNATIONAL COMPETITIVENESS

Campus Biotech is now firmly established as a key player in the Canton of Geneva's 2025–2027 Innovation Master Plan. Through the measure aimed at «facilitating access to the platforms of the Campus Biotech Geneva Foundation,» the Plan explicitly recognizes the strategic role of our scientific infrastructure in strengthening the cantonal ecosystem.

Our shared technology platforms are unique assets on a national scale. By lowering the barriers to accessing this cutting-edge equipment, particularly for innovative start-ups and SMEs, the cantonal scheme helps accelerate the development of new high value-added products and services.

This institutional recognition reinforces the FCBG's mission: to transform an infrastructure of excellence into a concrete lever for competitiveness and innovation in Geneva. By optimizing the use of our platforms, structuring clear and attractive access terms, and strengthening links with economic players, Campus Biotech contributes directly to entrepreneurial dynamism and the creation of skilled jobs in the fields of neuroscience, neurotechnology, and biotechnology.

Thus, Campus Biotech positions itself not only as an academic center of excellence, but also as a strategic infrastructure serving the canton's economic policy, fully aligned with the «infrastructure» and «ecosystem» axes of the Innovation Master Plan.

Access to the 2025-2027
Innovation Master Plan

Financials

2025: Overhaul of financial statements to improve the clarity of financial information.

The year 2025 confirms the soundness of the FCBG's financial model, while highlighting the challenges of adapting to medium-term changes. Growth in operating revenue reflects the operational success of the platforms, while pressure on public funding calls for a gradual evolution of the business model.

Solid operational performance despite tight budget constraints.

The 2025 fiscal year marks a pivotal milestone in the FCBG's financial trajectory. The accounts and financial statements have been redesigned and reformatted to improve readability and transparency of financial information. In a context marked by budget constraints among our institutional partners and the structural burden of rent and energy costs, the FCBG demonstrates the strength of its model. Revenue from scientific platforms increased by 25% to CHF 7.8 million, confirming the relevance of their positioning and their growing appeal to academic and clinical communities.

Free reserves on the rise: leverage under control for 2026.

The increase in the unrestricted reserve to CHF 1.8 million constitutes a major strategic lever, enabling the Foundation to absorb funding fluctuations and anticipate the budgetary challenges of 2026, as approved by the Foundation Board.

It should be noted that the FCBG manages the administrative and financial operations of the Genome Center, whose data are included in the Foundation's financial statements. Following the dissolution of the general partnership Health 2030, the platform's activities will continue into early 2026; future governance is currently being defined in consultation with stakeholders.

Summary of the Income Statement

Thousands of CHF	2025	2024
Operating income	30'194	28'668
Operating expenses	(32'341)	(30'380)
Operating income	**(2'147)**	**(1'712)**
Net result from financial activities	47	(6)
Non-recurring income / non-periodic	219	0
Income before changes in fund capital	**(1'882)**	**(1'717)**
Change in fund capital	5	(823)
Change in restricted reserves	2'539	1'350
Change in unrestricted reserves	**652**	**456**

Total 2025 assets: CHF 26.2 M

2025 Facilities and Infrastructure: CHF 19.2 M

The financial result is primarily attributable to foreign exchange gains. The extraordinary result is related to energy costs for 2024, partially offset by contributions from partners EPFL and UNIGE, additional financial assistance from DEE, and an adjustment to sublease rents.

Sources of funding for the Foundation in 2025

Breakdown of Operating Revenue

CHF 30'194 k



Distribution of charges in 2025

Breakdown of operating expenses

CHF 32'341 k



Rent and building charges	49%
Platforms management	13%
Personnel expenses	24%
Other operating expenses	14%

Financial Governance and Internal Control

KPMG 2025 « unmodified » audit opinion

KPMG highlighted the substantial improvements made in the formalization of processes, the monitoring of key controls, and the quality of financial information provided to governance bodies.

In 2024, the Foundation laid the groundwork for its internal control framework. The 2025 fiscal year marked a decisive milestone: the internal control system was completely overhauled, documented, and harmonized across the Foundation, thereby strengthening its alignment with institutional best practices. This consolidation enhances the robustness and consistency of the Foundation's financial governance.

Outlook for 2026: Toward a Dynamic and Operational System

By 2026, the internal monitoring programme will be fully operational. The Finance department will continue its transformation into a strategic partner for operational departments — capable of informing decisions and optimising resource allocation.

To this end, we will develop financial reports designed not only to meet regulatory and contractual requirements, but above all as genuine information and decision-support tools, tailored to the specific needs of each department.

These developments reflect a lasting commitment to rigour and transparency, in service of the Foundation's mission and the trust of its partners.

Vision

From vision to implementation

2026 will be a year of strategic execution. Following the Academic Council's adoption of an ambitious vision positioning Campus Biotech as an international center of excellence in neuroscience, neuroengineering, and artificial intelligence, priority will be given to its concrete implementation.

THE NEURO @CAMPUSBIOTECH INITIATIVE

At the heart of this dynamic, the launch of the **neuro** @CampusBiotech initiative will be an important objective. This simple and consistent name will provide clear visibility for all neuro activities on the site, integrating fundamental research, technological platforms, translational activities, clinical activities, and entrepreneurial innovation. The aim is not to create a new entity, but to affirm strategic, scientific, and communicational consistency.

In 2026, our actions will focus on three complementary areas:

- strengthen the Campus' scientific and human ecosystem by promoting the circulation of ideas, data, and skills, and by giving greater visibility to projects with a societal impact;
- consolidate and optimize platforms, ensuring their high availability, technological renewal, and adaptation to the 2025–2032 priorities, particularly in the fields of neuromodulatory interfaces, organoids, multimodal AI, and data;
- amplify clinical and entrepreneurial impact by supporting outpatient clinics, translational projects, and the site's attractiveness to startups and manufacturers.





COMPLETION OF BUILDING B4: A CATALYST FOR ENTREPRENEURIAL INNOVATION

The year 2026 will also see the completion of the new B4 building, a space dedicated primarily to startups and manufacturers. This strategic project marks a major evolution in the structure of the Biotech Campus by expanding its scope beyond academic researchers and clinicians to fully integrate entrepreneurs. Led mainly by our partner FONGIT, a space managed by Superlab ("Lab as a Service") will offer young companies a dynamic environment conducive to innovation and growth. It will thus constitute an essential anchor point for the development of new solutions in the life sciences.

TOWARDS A COMPREHENSIVE AND INTEGRATED ECOSYSTEM

Since its creation, the FCBG has built an environment of research excellence, bringing together world-renowned researchers around innovative projects. The year 2025 saw the integration of a new dimension with the arrival of patients at the heart of translational research initiatives. The next step will be to strengthen the presence of entrepreneurs and industrialists in order to create a unique continuum between fundamental research, clinical innovation, and industrial application.

Thanks to this dynamic, Campus Biotech will consolidate its position as a key strategic site for life sciences, not only for the canton of Geneva, but also for the whole of French-speaking Switzerland. This complementarity between researchers, clinicians, patients, and entrepreneurs will place our institution at the center of the major challenges facing medicine and health technologies of tomorrow.







Fondation Campus Biotech Geneva (FCBG)
9, Ch. des Mines | CH-1202 Geneva, Switzerland
contact@fcbg.ch | +41 58 201 02 00
fcbg.ch